Skip to content
2000
Volume 5, Issue 2
  • ISSN: 2210-2965
  • E-ISSN:

Abstract

Use of animal products to culture human stem cells poses risk of pathogens and other contaminations which may render stem cells therapeutically unsuitable. Hence, it is necessary to meet the standards of good manufacturing practices, clinical-grade like and xeno-free conditions. The protocol for culturing clinical grade stem cells needs to be modified so that maximum utilization can be done for stem cell therapies. Modifications can be in the media compositions, additional growth factors, small molecule compounds, and gene manipulations of the required transcription factors or the platform in which stem cells can grow. After the clinical grade standards are met it needs the approval of FDA for use as transplantation therapies. This review provides various methods and inventions for culturing clinical grade stem cells which have been patented.

Loading

Article metrics loading...

/content/journals/rpgm/10.2174/2210296505666151103204009
2015-08-01
2024-11-26
Loading full text...

Full text loading...

/content/journals/rpgm/10.2174/2210296505666151103204009
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test